A Phase 3 interventional study of 13 valent pneumococcal conjugate vaccine and 7vPnc pneumococcal conjugate vaccine in Vaccines, Pneumococcal, sponsored by Pfizer. Completed at 37 sites in United States. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-02-21.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal vaccine (13vPnC) compare to the 7-valent pneumococcal vaccine (7vPnC) and to compare the immune response to concomitant vaccines administered with 13vPnC and 7vPnC.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: 13 valent pneumococcal conjugate vaccine
Biological: 7vPnc pneumococcal conjugate vaccine
1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series
Percentages of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after the 3-dose infant series (7 months of age)
Geometric Mean Antibody Concentration in 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose
Antibody concentration/geometric mean concentration as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: 1 Month After the Toddler Dose
Percentage of Participants Achieving Predefined Antibody Levels for Haemophilus Influenzae Type b, Diphtheria Toxoid, and Pertussis Antigens in 13vPnC Group Relative to 7vPnC Group After the Infant Series
Predefined Antibody Levels for Haemophilus Influenzae Type b (\[Hib\] 0.15 µg/mL or 1.0 µg/mL), Diphtheria Toxoid (0.1 International Units \[IU\]/mL), and Pertussis antigens (Pertussis filamentous hemagglutinin \[FHA\] 40.5 Elisa Units \[EU\]/mL, Pertussis toxoid \[PT\] 16.5 EU/mL, Pertussis pertactin \[PRN\] 26 EU/mL).
Time frame: One Month After the Infant Series (7 months of age)
Percentage of Participants Reporting Pre-specified Systemic Events
Systemic events (any fever \[Fv\] ≥ 38 degrees Celsius \[C\], decreased (decr.) appetite, irritability, increased (incr.) sleep, decreased sleep, and hives \[urticaria\], use of antipyretic medication \[med\] to treat or prevent symptoms \[sx\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 7 days after each dose
Percentage of Participants Reporting Pre-specified Local Reactions
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (\[Sig.\], present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (\[Mod.\], 2.5 to 7.0 cm); Severe (\[Sev.\], \> 7.0 cm). Participants may have been represented in more than 1 category.
Time frame: Within 7 days after each dose
Percentage of Participants Achieving Predefined Antibody Levels for Concomitant Vaccine Antigens Induced by Measles, Mumps, Rubella, Varicella (MMR-V) and Haemophilus Influenzae Type b (Hib)
Time frame: One month after toddler dose (13 to 16 months of age)
Geometric Mean Antibody Concentration of Hib PRP in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
Time frame: one month after the toddler dose
Geometric Mean Antibody Concentration of Measles, Mumps, and Varicella ELISA in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
Normalization was performed for unit of measure "index value" as Index Value of 1.00 = 10 mIU/mL.
Time frame: one month after the toddler dose
Geometric Mean Antibody Concentration of Rubella in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
Time frame: one month after the toddler dose
Percentage of Participants Achieving Functional Antibody Titer ≥1:8 as Measured by Opsonophagocytic Activity Assay (OPA) in 13vPnC Group Relative to 7vPnC Group the 3-Dose Infant Series and the Toddler Dose
Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after infant series and one month after toddler dose
Geometric Mean Titer (GMT) as Measured by Opsonophagocytic Activity Assay (OPA) in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series and the Toddler Dose
Geometric mean titer (GMT) as measured by opsonophagocytic activity assay (OPA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: one month after the infant series and the toddler dose
Participants were recruited in the United States from September 2006 to January 2008.
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 334 | 332 |
| Vaccinated dose 1 | 332 | 331 |
| Vaccinated dose 2 | 309 | 305 |
| Vaccinated dose 3 | 298 | 300 |
| Completed | 294 | 290 |
| Not completed | 40 | 42 |
| Withdrew: Withdrawal by subject | 13 | 15 |
| Withdrew: Failed to return | 8 | 13 |
| Withdrew: Lost to follow-up | 6 | 5 |
| Withdrew: Protocol violation | 3 | 7 |
| Withdrew: Lost kaiser coverage | 4 | 0 |
| Withdrew: Child relocated | 1 | 0 |
| Withdrew: Consent was not received | 1 | 0 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Physician decision | 1 | 1 |
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 294 | 290 |
| Withdrawn after infant series | 22 | 25 |
| Vaccinated toddler dose | 272 | 265 |
| Completed | 264 | 252 |
| Not completed | 30 | 38 |
| Withdrew: Lost to follow-up | 5 | 8 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Failed to return | 1 | 2 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawn after infant series | 22 | 25 |
Percentages of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Common Serotypes - Serotype 4 (n=252,251) | 94.4 (90.9 to 96.9) | 98.0 (95.4 to 99.4) |
| Common Serotypes - Serotype 6B (n=252,250) | 87.3 (82.5 to 91.1) | 92.8 (88.9 to 95.7) |
| Common Serotypes - Serotype 9V (n=252,252) | 90.5 (86.2 to 93.8) | 98.4 (96.0 to 99.6) |
| Common Serotypes - Serotype 14 (n=251,252) | 97.6 (94.9 to 99.1) | 97.2 (94.4 to 98.9) |
| Common Serotypes - Serotype 18C (n=252,252) | 96.8 (93.8 to 98.6) | 98.4 (96.0 to 99.6) |
| Common Serotypes - Serotype 19F (n=252,251) | 98.0 (95.4 to 99.4) | 97.6 (94.9 to 99.1) |
| Common Serotypes - Serotype 23F (n=252,252) | 90.5 (86.2 to 93.8) | 94.0 (90.4 to 96.6) |
| Additional Serotypes - Serotype 1 (n=252,248) | 95.6 (92.3 to 97.8) | 1.6 (0.4 to 4.1) |
| Additional Serotypes - Serotype 3 (n=249,241) | 63.5 (57.1 to 69.4) | 4.6 (2.3 to 8.0) |
| Additional Serotypes - Serotype 5 (n=252,197) | 89.7 (85.2 to 93.1) | 31.0 (24.6 to 37.9) |
| Additional Serotypes - Serotype 6A (n=252,240) | 96.0 (92.8 to 98.1) | 42.5 (36.2 to 49.0) |
| Additional Serotypes - Serotype 7F (n=252,248) | 98.4 (96.0 to 99.6) | 2.8 (1.1 to 5.7) |
| Additional Serotypes - Serotype 19A (n=251,238) | 98.4 (96.0 to 99.6) | 86.6 (81.6 to 90.6) |
Antibody concentration/geometric mean concentration as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| μg/mL | 13vPnC | 7vPnC |
|---|---|---|
| Common Serotypes - Serotype 4 (n=235,223) | 3.73 (3.28 to 4.24) | 5.49 (4.91 to 6.13) |
| Common Serotypes - Serotype 6B (n=234,223) | 11.53 (9.99 to 13.30) | 15.63 (13.80 to 17.69) |
| Common Serotypes - Serotype 9V (n=234,223) | 2.62 (2.32 to 2.94) | 3.63 (3.25 to 4.05) |
| Common Serotypes - Serotype 14 (n=235,223) | 9.11 (7.95 to 10.45) | 12.72 (11.22 to 14.41) |
| Common Serotypes - Serotype 18C (n=236,223) | 3.20 (2.82 to 3.64) | 4.70 (4.18 to 5.28) |
| Common Serotypes - Serotype 19F (n=235,223) | 6.60 (5.85 to 7.44) | 5.60 (4.87 to 6.43) |
| Common Serotypes - Serotype 23F (n=234,222) | 5.07 (4.41 to 5.83) | 7.84 (6.91 to 8.90) |
| Additional Serotypes - Serotype 1 (n=235,223) | 5.06 (4.43 to 5.80) | 0.03 (0.03 to 0.03) |
| Additional Serotypes - Serotype 3 (n=232,223) | 0.94 (0.83 to 1.05) | 0.07 (0.05 to 0.08) |
| Additional Serotypes - Serotype 5 (n=235,223) | 3.72 (3.31 to 4.18) | 0.55 (0.47 to 0.64) |
| Additional Serotypes - Serotype 6A (n=235,223) | 8.20 (7.30 to 9.20) | 1.87 (1.60 to 2.19) |
| Additional Serotypes - Serotype 7F (n=235,223) | 5.67 (5.01 to 6.42) | 0.05 (0.04 to 0.05) |
| Additional Serotypes - Serotype 19A (n=236,223) | 8.55 (7.64 to 9.56) | 3.54 (3.15 to 3.98) |
Predefined Antibody Levels for Haemophilus Influenzae Type b (\[Hib\] 0.15 µg/mL or 1.0 µg/mL), Diphtheria Toxoid (0.1 International Units \[IU\]/mL), and Pertussis antigens (Pertussis filamentous hemagglutinin \[FHA\] 40.5 Elisa Units \[EU\]/mL, Pertussis toxoid \[PT\] 16.5 EU/mL, Pertussis pertactin \[PRN\] 26 EU/mL).
| Percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Hib 0.15 µg/mL (n=237,230) | 97.9 (95.1 to 99.3) | 97.8 (95.0 to 99.3) |
| Hib 1.0 µg/mL (n=237,230) | 77.6 (71.8 to 82.8) | 78.3 (72.4 to 83.4) |
| Diphtheria [IU]/mL (n=233,230) | 95.7 (92.2 to 97.9) | 96.1 (92.7 to 98.2) |
| FHA [EU]/mL (n=239,240) | 96.7 (93.5 to 98.5) | 95.0 (91.4 to 97.4) |
| PT [EU]/mL (n=239,240) | 94.1 (90.4 to 96.8) | 95.0 (91.4 to 97.4) |
| PRN [EU]/mL (n=239,240) | 93.7 (89.9 to 96.4) | 95.8 (92.5 to 98.0) |
| percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Measles ≥1.10 I.V. (n=221,210) | 96.4 (93.0 to 98.4) | 97.1 (93.9 to 98.9) |
| Mumps ≥1.10 I.V. (n=221,210) | 76.5 (70.3 to 81.9) | 72.9 (66.3 to 78.7) |
| Rubella ≥15 IU/mL (n=209,204) | 91.9 (87.3 to 95.2) | 90.7 (85.8 to 94.3) |
| Varicella ≥1.09 I.V. (n=221,210) | 26.7 (21.0 to 33.0) | 21.9 (16.5 to 28.1) |
| Hib (PRP) 0.15 µg/mL (n=230,214) | 100.0 (98.4 to 100.0) | 100.0 (98.3 to 100.0) |
| Hib (PRP) 1.0 µg/mL (n=230,214) | 90.4 (85.9 to 93.9) | 92.1 (87.6 to 95.3) |
| µg/mL | 13vPnC | 7vPnC |
|---|---|---|
| Geometric Mean Antibody Concentration of Hib PRP in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose | 6.84 (5.85 to 7.99) | 7.30 (6.21 to 8.59) |
Normalization was performed for unit of measure "index value" as Index Value of 1.00 = 10 mIU/mL.
| index value | 13vPnC | 7vPnC |
|---|---|---|
| Measles | 1.98 (1.81 to 2.16) | 2.06 (1.90 to 2.23) |
| Mumps | 1.32 (1.19 to 1.46) | 1.32 (1.20 to 1.45) |
| Varicella | 0.74 (0.69 to 0.79) | 0.73 (0.69 to 0.77) |
| IU/mL | 13vPnC | 7vPnC |
|---|---|---|
| Geometric Mean Antibody Concentration of Rubella in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose | 76.53 (64.55 to 90.72) | 97.69 (82.28 to 115.98) |
Systemic events (any fever \[Fv\] ≥ 38 degrees Celsius \[C\], decreased (decr.) appetite, irritability, increased (incr.) sleep, decreased sleep, and hives \[urticaria\], use of antipyretic medication \[med\] to treat or prevent symptoms \[sx\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
| Percentage of participants | 13vPnC Dose 1 | 7vPnC Dose 1 | 13vPnC Dose 2 | 7vPnC Dose 2 | 13vPnC Dose 3 | 7vPnC Dose 3 | 13vPnC Toddler Dose | 7vPnC Toddler Dose |
|---|---|---|---|---|---|---|---|---|
| Fv≥38°C but ≤39°C(n=196,203,146,151,123,106,99,76 | 24.0 | 21.2 | 43.2 | 40.4 | 39.8 | 37.7 | 53.5 | 51.3 |
| Fv>39°C but ≤40°C(n=177,187,118,123,94,81,61,48) | 2.8 | 0.0 | 2.5 | 4.9 | 8.5 | 2.5 | 6.6 | 12.5 |
| Fv >40°C (n=174,187,116,121,87,80,60,45) | 0.0 | 0.0 | 0.0 | 0.8 | 0.0 | 1.3 | 1.7 | 0.0 |
| Decr. appetite (n=228,238,177,174,147,136,116,110) | 54.8 | 45.4 | 59.9 | 52.3 | 59.2 | 59.6 | 65.5 | 73.6 |
| Irritability (n=289,290,236,236,216,218,199,175) | 89.6 | 85.9 | 89.8 | 91.5 | 88.4 | 92.2 | 92.0 | 93.1 |
| Incr. sleep (n=268,270,203,200,164,149,115,109) | 79.5 | 78.5 | 79.3 | 73.5 | 71.3 | 69.8 | 70.4 | 74.3 |
| Decr. sleep (n=221,236,169,172,154,134,113,95) | 45.7 | 47.9 | 49.1 | 55.8 | 60.4 | 63.4 | 58.4 | 64.2 |
| Hives (urticaria) (n=178,188,118,120,89,79,62,47) | 1.7 | 1.1 | 2.5 | 0.0 | 4.5 | 0.0 | 4.8 | 6.4 |
| Med-treat sx (n=257,266,221,221,203,187,162,138) | 78.6 | 71.8 | 82.4 | 81.9 | 82.3 | 85.6 | 84.0 | 87.7 |
| Med-prevent sx (n=272,274,233,231,202,189,164,162) | 75.0 | 74.8 | 86.7 | 83.5 | 81.2 | 84.1 | 88.4 | 90.7 |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (\[Sig.\], present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (\[Mod.\], 2.5 to 7.0 cm); Severe (\[Sev.\], \> 7.0 cm). Participants may have been represented in more than 1 category.
| Percentage of participants | 13vPnC Dose 1 | 7vPnC Dose 1 | 13vPnC Dose 2 | 7vPnC Dose 2 | 13vPnC Dose 3 | 7vPnC Dose 3 | 13vPnC Toddler Dose | 7vPnC Toddler Series |
|---|---|---|---|---|---|---|---|---|
| Tenderness-Any (n=264,270,200,216,178,173,149,147) | 72.7 | 72.2 | 77.0 | 75.9 | 78.7 | 80.9 | 81.2 | 84.4 |
| Tenderness-Sig. (n=182,195,123,131,91,86,65,49) | 13.7 | 9.2 | 10.6 | 11.5 | 8.8 | 9.3 | 15.4 | 12.2 |
| Swelling-Any (n=201,216,141,146,116,103,91,73) | 27.4 | 23.6 | 31.2 | 29.5 | 37.9 | 36.9 | 44.0 | 50.7 |
| Swelling-Mild (n=199,212,141,142,113,103,90,71) | 23.1 | 21.2 | 29.8 | 26.1 | 35.4 | 36.9 | 43.3 | 46.5 |
| Swelling-Mod. (n=176,193,118,126,91,82,68,49) | 6.8 | 5.2 | 5.1 | 7.1 | 6.6 | 6.1 | 14.7 | 14.3 |
| Swelling-Sev. (n=172,187,116,120,87,79,59,44) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Redness-Any (n=202,223,155,164,131,118,103,87) | 35.6 | 32.3 | 45.2 | 37.8 | 48.9 | 50.0 | 54.4 | 65.5 |
| Redness-Mild (n=200,220,155,162,128,117,102,85) | 34.5 | 31.4 | 44.5 | 37.0 | 47.7 | 48.7 | 53.9 | 63.5 |
| Redness-Mod. (n=177,191,117,124,91,80,62,50) | 4.5 | 2.6 | 1.7 | 3.2 | 5.5 | 5.0 | 8.1 | 14.0 |
| Redness-Sev. (n=173,186,116,120,87,79,59,44) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| percentage of participants | 13vPnC After Infant Series | 7vPnC After Infant Series | 13vPnC After Toddler Dose | 7vPnC After Toddler Dose |
|---|---|---|---|---|
| Common Serotypes - Serotype 4 (n=92,92,88,92) | 97.8 (92.4 to 99.7) | 98.9 (94.1 to 100.0) | 98.9 (93.8 to 100.0) | 98.9 (94.1 to 100.0) |
| Common Serotypes - Serotype 6B (n=94,94,92,95) | 98.9 (94.2 to 100.0) | 100.0 (96.2 to 100.0) | 98.9 (94.1 to 100.0) | 100.0 (96.2 to 100.0) |
| Common Serotypes - Serotype 9V (n=93,94,90,94) | 100.0 (96.1 to 100.0) | 98.9 (94.2 to 100.0) | 98.9 (94.0 to 100.0) | 100.0 (96.2 to 100.0) |
| Common Serotypes - Serotype 14 (n=94,94,92,96) | 100.0 (96.2 to 100.0) | 100.0 (96.2 to 100.0) | 100.0 (96.1 to 100.0) | 100.0 (96.2 to 100.0) |
| Common Serotypes - Serotype 18C (n=94,94,91,96) | 100.0 (96.2 to 100.0) | 100.0 (96.2 to 100.0) | 98.9 (94.0 to 100.0) | 100.0 (96.2 to 100.0) |
| Common Serotypes - Serotype 19F (n=94,94,92,96) | 90.4 (82.6 to 95.5) | 92.6 (85.3 to 97.0) | 96.7 (90.8 to 99.3) | 94.8 (88.3 to 98.3) |
| Common Serotypes - Serotype 23F (n=94,94,90,92) | 98.9 (94.2 to 100.0) | 98.9 (94.2 to 100.0) | 98.9 (94.0 to 100.0) | 100.0 (96.1 to 100.0) |
| Additional Serotypes - Serotype 1 (n=92,92,89,92) | 98.9 (94.1 to 100.0) | 9.8 (4.6 to 17.8) | 98.9 (93.9 to 100.0) | 12.0 (6.1 to 20.4) |
| Additional Serotypes - Serotype 3 (n=94,94,91,96) | 96.8 (91.0 to 99.3) | 21.3 (13.5 to 30.9) | 97.8 (92.3 to 99.7) | 43.8 (33.6 to 54.3) |
| Additional Serotypes - Serotype 5 (n=91,93,91,96) | 92.3 (84.8 to 96.9) | 2.2 (0.3 to 7.6) | 98.9 (94.0 to 100.0) | 5.2 (1.7 to 11.7) |
| Additional Serotypes - Serotype 6A (n=94,94,92,96) | 100.0 (96.2 to 100.0) | 77.7 (67.9 to 85.6) | 98.9 (94.1 to 100.0) | 94.8 (88.3 to 98.3) |
| Additional Serotypes - Serotype 7F (n=94,89,91,92) | 100.0 (96.2 to 100.0) | 76.4 (66.2 to 84.8) | 100.0 (96.0 to 100.0) | 80.4 (70.9 to 88.0) |
| Additional Serotypes-Serotype 19A (n=93,92,91,94) | 91.4 (83.8 to 96.2) | 16.3 (9.4 to 25.5) | 97.8 (92.3 to 99.7) | 53.2 (42.6 to 63.6) |
Geometric mean titer (GMT) as measured by opsonophagocytic activity assay (OPA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| titer | 13vPnC After the Infant Series | 7vPnC After the Infant Series | 13vPnC After the Toddler Dose | 7vPnC After the Toddler Dose |
|---|---|---|---|---|
| Common Serotypes -Serotype 4 (n=92,92,88,92) | 359.32 (276.04 to 467.72) | 535.68 (421.13 to 681.37) | 1179.98 (847.34 to 1643.20) | 1492.46 (1114.40 to 1998.78) |
| Common Serotypes - Serotype 6B (n=94,94,92,95) | 1054.65 (817.34 to 1360.87) | 1513.66 (1206.64 to 1898.81) | 3099.51 (2337.02 to 4110.79) | 4066.22 (3243.42 to 5097.76) |
| Common Serotypes - Serotype 9V (n=93,94,90,94) | 4035.40 (2932.68 to 5552.75) | 3259.01 (2288.43 to 4641.25) | 11856.03 (8809.85 to 15955.49) | 18032.33 (14124.99 to 23020.53) |
| Common Serotypes - Serotype 14 (n=94,94,92,96) | 1240.41 (934.93 to 1645.69) | 1480.55 (1133.40 to 1934.02) | 2002.23 (1452.54 to 2759.93) | 2365.87 (1870.56 to 2992.34) |
| Common Serotypes - Serotype 18C (n=94,94,91,96) | 275.59 (210.33 to 361.10) | 375.64 (291.68 to 483.75) | 993.27 (754.08 to 1308.33) | 1722.16 (1326.59 to 2235.67) |
| Common Serotypes - Serotype 19F (n=94,94,92,96) | 54.42 (40.20 to 73.65) | 44.92 (33.90 to 59.52) | 199.65 (144.22 to 276.38) | 167.20 (121.35 to 230.37) |
| Common Serotypes - Serotype 23F (n=94,94,90,92) | 791.07 (604.96 to 1034.44) | 923.56 (708.59 to 1203.74) | 2723.25 (1960.67 to 3782.41) | 4981.68 (3885.71 to 6386.76) |
| Additional Serotypes - Serotype 1 (n=92,92,89,92) | 51.83 (38.84 to 69.16) | 4.41 (4.06 to 4.80) | 164.23 (113.83 to 236.93) | 5.01 (4.22 to 5.96) |
| Additional Serotypes - Serotype 3 (n=94,94,91,96) | 120.67 (92.38 to 157.62) | 6.70 (5.27 to 8.52) | 380.41 (300.19 to 482.08) | 11.81 (8.68 to 16.08) |
| Additional Serotypes - Serotype 5 (n=91,93,91,96) | 90.86 (67.10 to 123.02) | 4.15 (3.94 to 4.38) | 300.41 (229.39 to 393.40) | 4.69 (3.99 to 5.51) |
| Additional Serotypes - Serotype 6A (n=94,94,92,96) | 979.68 (783.04 to 1225.71) | 100.35 (66.22 to 152.08) | 2241.79 (1706.71 to 2944.63) | 538.54 (374.83 to 773.75) |
| Additional Serotypes - Serotype 7F (n=94,89,91,92) | 9493.77 (7339.13 to 12280.98) | 128.00 (79.55 to 205.97) | 11629.44 (9053.62 to 14938.11) | 267.84 (164.49 to 436.11) |
| Additional Serotypes-Serotype 19A (n=93,92,91,94) | 151.94 (105.16 to 219.52) | 6.53 (5.01 to 8.50) | 1024.00 (774.12 to 1354.54) | 28.65 (18.58 to 44.17) |
Collected over Adverse events were collected throughout the study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC Infant Series | — | 17/332 (5.1%) | 272/332 (81.9%) |
| 7vPnC Infant Series | — | 16/331 (4.8%) | 263/331 (79.5%) |
| 13vPnC Post Infant Series | — | 5/332 (1.5%) | 31/332 (9.3%) |
| 7vPnC Post Infant Series | — | 7/330 (2.1%) | 29/330 (8.8%) |
| 13vPnC Toddler Series | — | 3/267 (1.1%) | 183/267 (68.5%) |
| 7vPnC Toddler Series | — | 4/258 (1.6%) | 163/258 (63.2%) |
| 13vPnC 6-Month Follow-up | — | 9/330 (2.7%) | 11/330 (3.3%) |
| 7vPnC 6-Month Follow-up | — | 5/329 (1.5%) | 10/329 (3%) |
| Event | 13vPnC Infant Series | 7vPnC Infant Series | 13vPnC Post Infant Series | 7vPnC Post Infant Series | 13vPnC Toddler Series | 7vPnC Toddler Series | 13vPnC 6-Month Follow-up | 7vPnC 6-Month Follow-up |
|---|---|---|---|---|---|---|---|---|
| BronchiolitisInfections and infestations | 4/332 | 6/331 | 0/332 | 2/330 | 0/267 | 0/258 | 1/330 | 0/329 |
| Respiratory syncytial virus bronchiolitisInfections and infestations | 3/332 | 2/331 | 0/332 | 0/330 | 0/267 | 0/258 | 1/330 | 1/329 |
| Status asthmaticusRespiratory, thoracic and mediastinal disorders | 0/332 | 0/331 | 1/332 | 2/330 | 1/267 | 0/258 | 0/330 | 1/329 |
| Respiratory syncytial virus infectionInfections and infestations | 0/332 | 2/331 | 0/332 | 0/330 | 0/267 | 0/258 | 1/330 | 0/329 |
| PyrexiaGeneral disorders | 2/332 | 0/331 | 0/332 | 0/330 | 0/267 | 0/258 | 0/330 | 0/329 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/332 | 0/331 | 0/332 | 0/330 | 0/267 | 1/258 | 1/330 | 1/329 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/332 | 1/331 | 0/332 | 0/330 | 0/267 | 1/258 | 0/330 | 0/329 |
| DehydrationMetabolism and nutrition disorders | 0/332 | 0/331 | 0/332 | 0/330 | 0/267 | 1/258 | 0/330 | 0/329 |
| Febrile convulsionNervous system disorders | 1/332 | 0/331 | 1/332 | 0/330 | 0/267 | 1/258 | 0/330 | 0/329 |
| GastroenteritisInfections and infestations | 0/332 | 0/331 | 0/332 | 0/330 | 0/267 | 1/258 | 0/330 | 0/329 |
| Event | 13vPnC Infant Series | 7vPnC Infant Series | 13vPnC Post Infant Series | 7vPnC Post Infant Series | 13vPnC Toddler Series | 7vPnC Toddler Series | 13vPnC 6-Month Follow-up | 7vPnC 6-Month Follow-up |
|---|---|---|---|---|---|---|---|---|
| IrritabilityGeneral disorders | 259/289 | 249/290 | — | — | 183/199 | 163/175 | — | — |
| IrritabilityGeneral disorders | 191/216 | 201/218 | — | — | — | — | — | — |
| IrritabilityGeneral disorders | 212/236 | 216/236 | — | — | — | — | — | — |
| Tenderness (Any)Skin and subcutaneous tissue disorders | 192/264 | 195/270 | — | — | 121/149 | 124/147 | — | — |
| Tenderness (Any)Skin and subcutaneous tissue disorders | 140/178 | 140/173 | — | — | — | — | — | — |
| Increased sleepGeneral disorders | 213/268 | 212/270 | — | — | 81/115 | 81/109 | — | — |
| Increased sleepGeneral disorders | 161/203 | 147/200 | — | — | — | — | — | — |
| Tenderness (Any)Skin and subcutaneous tissue disorders | 154/200 | 164/216 | — | — | — | — | — | — |
| Decreased appetiteGeneral disorders | 125/228 | 108/238 | — | — | 76/116 | 81/110 | — | — |
| Increased sleepGeneral disorders | 117/164 | 104/149 | — | — | — | — | — | — |
| Age Continuous(months) | 13vPnC | 7vPnC | Total |
|---|---|---|---|
| Mean | 2.1 ± 0.3 | 2.1 ± 0.3 | 2.1 ± 0.3 |
| Sex: Female, Male(Participants) | 13vPnC | 7vPnC | Total |
|---|---|---|---|
| Female | 165 | 139 | 304 |
| Male | 169 | 193 | 362 |
The record gives a start of Sep 2006, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2013, 4 years 8 months after primary completion. A results delay was requested in Feb 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine